ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Intermediate rectal dose is associated with late toxicity after prostate SBRT: a dose-volume histogram principal component analysis.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate whether principal component analysis (PCA) of rectal and bladder dose-volume histograms (DVHs) identifies dose regions associated with late toxicity after prostate stereotactic body radiotherapy (SBRT). METHODS/PATIENTS: This retrospective single-institution study included 106 patients with linked clinical and dosimetric data after prostate SBRT to 36.25 Gy in five fractions. PCA was applied separately to whole-organ and wall-based rectal and bladder DVHs. Associations with late grade ≥ 2 gastrointestinal (GI) and genitourinary (GU) toxicity at 12 months were explored using Spearman correlation, ROC analysis and deliberately limited logistic regression. Toxicity was extracted retrospectively from institutional follow-up records scored according to CTCAE v5.0.
resultsAmong 84 patients with 12-month follow-up in the DVH-linked dosimetric cohort, grade ≥ 2 toxicity was uncommon, with 3 GI events (3.6%) and 2 GU events (2.4%). Intermediate-dose rectal metrics showed the strongest exploratory signal for late GI toxicity, particularly rectal V18.1 Gy (AUC 0.868, 95% CI 0.740-0.997) and V29 Gy (AUC 0.827). These estimates are based on very few events and should not be interpreted as validated predictive performance or as evidence of a new planning threshold. No bladder or bladder-wall metric showed clinically meaningful discrimination for GU toxicity.
conclusionsIntermediate whole-rectum dose was associated with late GI toxicity in this low-event SBRT cohort, but the findings are exploratory and require validation. No isolated dosimetric predictor of late GU toxicity was identified.
Indexed as
Identifiers
42545625What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.